Literature DB >> 26183622

Surgical treatment for intrahepatic cholangiocarcinoma.

Takahiro Uenishi1, Takatsugu Yamamoto, Shigekazu Takemura, Shoji Kubo.   

Abstract

Despite surgical treatment for intrahepatic cholangiocarcinoma (ICC) becoming more widely available, the prognosis after hepatic resection for ICC remains poor. Because ICC is relatively rare, the TNM staging system for ICC was finally established in the 2000s. Resection margin status and lymph node metastases are important prognostic factors after surgery for ICC; however, the true impact of wide resection margins or lymph node dissection on postoperative survival is unclear. Although adjuvant chemotherapy can improve the postoperative prognosis of patients with various types of cancer, no standard regimen has been developed for ICC. Over 50 % of patients suffer postoperative recurrence, even after curative resection, and no effective treatment for recurrent ICC has been established. Therefore, despite advances in imaging studies and hepatobiliary surgery, significant challenges remain in improving the prognosis of patients with ICC.

Entities:  

Mesh:

Year:  2014        PMID: 26183622     DOI: 10.1007/s12328-014-0460-z

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  69 in total

1.  A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer.

Authors:  Takashi Sasaki; Hiroyuki Isayama; Yousuke Nakai; Yukiko Ito; Ichiro Yasuda; Nobuo Toda; Hirofumi Kogure; Keiji Hanada; Hiroyuki Maguchi; Naoki Sasahira; Hideki Kamada; Tsuyoshi Mukai; Yoshihiro Okabe; Osamu Hasebe; Iruru Maetani; Kazuhiko Koike
Journal:  Cancer Chemother Pharmacol       Date:  2013-01-26       Impact factor: 3.333

2.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

3.  Macroscopic types of intrahepatic cholangiocarcinoma: clinicopathologic features and surgical outcomes.

Authors:  Kazuhiro Hirohashi; Takahiro Uenishi; Shoji Kubo; Takatsugu Yamamoto; Hiromu Tanaka; Taichi Shuto; Hiroaki Kinoshita
Journal:  Hepatogastroenterology       Date:  2002 Mar-Apr

4.  Adjuvant chemotherapy in resectable cholangiocarcinoma patients.

Authors:  Kosin Wirasorn; Thundon Ngamprasertchai; Narong Khuntikeo; Ake Pakkhem; Piti Ungarereevittaya; Jarin Chindaprasirt; Aumkhae Sookprasert
Journal:  J Gastroenterol Hepatol       Date:  2013-12       Impact factor: 4.029

5.  Predictive factors for long-term survival in patients with intrahepatic cholangiocarcinoma.

Authors:  T Isa; T Kusano; H Shimoji; Y Takeshima; Y Muto; M Furukawa
Journal:  Am J Surg       Date:  2001-06       Impact factor: 2.565

Review 6.  Intrahepatic cholangiocarcinoma: macroscopic type and stage classification.

Authors:  Susumu Yamasaki
Journal:  J Hepatobiliary Pancreat Surg       Date:  2003

7.  Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection.

Authors:  Alfredo Guglielmi; Andrea Ruzzenente; Tommaso Campagnaro; Silvia Pachera; Alessandro Valdegamberi; Paola Nicoli; Alessandro Cappellani; Giulio Malfermoni; Calogero Iacono
Journal:  World J Surg       Date:  2009-06       Impact factor: 3.352

8.  Intrahepatic cholangiocarcinoma: analysis of 44 consecutive resected cases including 5 cases with repeat resections.

Authors:  Akio Saiura; Junji Yamamoto; Norihiro Kokudo; Rintaro Koga; Makoto Seki; Naoki Hiki; Kazuhiko Yamada; Takeshi Natori; Toshiharu Yamaguchi
Journal:  Am J Surg       Date:  2009-05-09       Impact factor: 2.565

9.  Clinicopathological prognostic factors and impact of surgical treatment of mass-forming intrahepatic cholangiocarcinoma.

Authors:  Shohachi Suzuki; Takanori Sakaguchi; Yoshihiro Yokoi; Kazuya Okamoto; Kiyotaka Kurachi; Yasuo Tsuchiya; Takuya Okumura; Hiroyuki Konno; Satoshi Baba; Satoshi Nakamura
Journal:  World J Surg       Date:  2002-03-26       Impact factor: 3.352

10.  Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study.

Authors:  Tania M Welzel; Barry I Graubard; Hashem B El-Serag; Yasser H Shaib; Ann W Hsing; Jessica A Davila; Katherine A McGlynn
Journal:  Clin Gastroenterol Hepatol       Date:  2007-08-06       Impact factor: 11.382

View more
  7 in total

Review 1.  Staging of intrahepatic cholangiocarcinoma.

Authors:  Sean M Ronnekleiv-Kelly; Timothy M Pawlik
Journal:  Hepatobiliary Surg Nutr       Date:  2017-02       Impact factor: 7.293

2.  Low Incidence of Lymph Node Metastasis After Resection of Hepatitis Virus-Related Intrahepatic Cholangiocarcinoma.

Authors:  Hiroya Iida; Masaki Kaibori; Shogo Tanaka; Shigekazu Takemura; Hiroshi Wada; Fumitoshi Hirokawa; Takuya Nakai; Michihiro Hayashi; Hidetoshi Eguchi; Shoji Kubo
Journal:  World J Surg       Date:  2017-04       Impact factor: 3.352

3.  Ex vivo human bile duct radiofrequency ablation with a bipolar catheter.

Authors:  Mustafa Atar; Abdurrahman Kadayifci; Ebubekir Daglilar; Catherine Hagen; Carlos Fernandez-Del Castillo; William R Brugge
Journal:  Surg Endosc       Date:  2017-12-20       Impact factor: 4.584

4.  Expression of VEGFR-3 in intrahepatic cholangiocarcinoma correlates with unfavorable prognosis through lymphangiogenesis.

Authors:  Meng Sha; Seogsong Jeong; Xiao-Song Chen; Ying Tong; Jie Cao; Han-Yong Sun; Lei Xia; Ning Xu; Xin Wang; Long-Zhi Han; Zhi-Feng Xi; Jian-Jun Zhang; Xiao-Ni Kong; Qiang Xia
Journal:  Int J Biol Sci       Date:  2018-07-27       Impact factor: 6.580

5.  Preoperative CEA levels are supplementary to CA19-9 levels in predicting prognosis in patients with resectable intrahepatic cholangiocarcinoma.

Authors:  Chaobin He; Yu Zhang; Yunda Song; Jun Wang; Kaili Xing; Xiaojun Lin; Shengping Li
Journal:  J Cancer       Date:  2018-08-06       Impact factor: 4.207

6.  Piperlongumine induces autophagy in biliary cancer cells via reactive oxygen species-activated Erk signaling pathway.

Authors:  San-Yuan Chen; Hsin-Yi Huang; Han-Pei Lin; Chiung-Yao Fang
Journal:  Int J Mol Med       Date:  2019-08-23       Impact factor: 4.101

7.  Should Lymph Nodes Be Retrieved in Patients with Intrahepatic Cholangiocarcinoma? A Collaborative Korea-Japan Study.

Authors:  Chang Moo Kang; Kyung-Suk Suh; Nam-Joon Yi; Tae Ho Hong; Sang Jae Park; Keun Soo Ahn; Hiroki Hayashi; Sae Byeol Choi; Chi-Young Jeong; Takeshi Takahara; Shigehiro Shiozaki; Young Hoon Roh; Hee Chul Yu; Takumi Fukumoto; Ryusei Matsuyama; Uyama Naoki; Kazuki Hashida; Hyung Il Seo; Takehiro Okabayashi; Tomoo Kitajima; Sohei Satoi; Hiroaki Nagano; Hongbeom Kim; Kaoru Taira; Shoji Kubo; Dong Wook Choi
Journal:  Cancers (Basel)       Date:  2021-01-25       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.